Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720787 | 0.85 | SRD5A2 (0.43) | MCHR1SRD5A2ALDH1A1HRH3 | |
| SCHEMBL14721353 | 0.83 | SRD5A2 (0.42) | MCHR1SRD5A2HRH3SRD5A1 | |
| SCHEMBL14720897 | 0.79 | SRD5A2 (0.38) | MCHR1SRD5A2HRH3SRD5A1FPR2 | |
| SCHEMBL14720584 | 0.78 | SRD5A2 (0.47) | MCHR1SRD5A2HRH3SRD5A1OGA | |
| SCHEMBL14720476 | 0.74 | SRD5A2 (0.35) | MCHR1SRD5A2HRH3SRD5A1 | |
| SCHEMBL14720777 | 0.73 | MCHR1 (0.44) | MCHR1SRD5A2HRH3 | |
| SCHEMBL14721354 | 0.72 | HRH3 (0.47) | SRD5A2HRH3OGA | |
| SCHEMBL14720870 | 0.72 | MCHR1 (0.52) | MCHR1SRD5A2HRH3SRD5A1 | |
| Hydrochloric Acid SCHEMBL14720474 | 0.72 | POLB (0.47) | SRD5A2ALDH1A1HRH3 | |
| SCHEMBL14722734 | 0.71 | OGA (0.52) | MCHR1SRD5A2ALDH1A1HRH3SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |